RxDoctor Payments Data

William Baumgartl, MD

Interventional Pain Medicine · Antioch, CANPI 1528004496

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,611 of the $12,900 with a category attached, or 82.3%. It is spread thinly across 38 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,970 and has fallen 73.4% since, to $789 in 2025.

$12,900in general payments, 2019–2025

Across 389 payments — averaging $33.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nalu Medical, Inc.$2K
  • Nevro Corp.$2K
  • Boston Scientific$2K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Scilex Pharmaceuticals Inc.$1K
  • Collegium Pharmaceutical, Inc.$561
  • plus $4K from 32 others

What the payments were for

  • Consulting fees$1,2009%
  • Travel & lodging$1,0768%
  • Food & beverage$10,61182%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,900 in reported general payments places this provider in the 80th percentile of 188 interventional pain medicine providers in California.

See all interventional pain medicine providers in California

Medicare billing

Part B allowed, 2024
$84,703
Medicare patients
152
Services billed
555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide22$20,864
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen317$10,233
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen109$4,734
Zonisamide64$2,109
Tizanidine Hcl109$1,072
Gabapentin75$1,044
Lidocaine11$747
Baclofen22$708
Pregabalin47$685
Oxycodone Hcl42$614
Naproxen14$605
Cyclobenzaprine Hcl55$417
Tramadol Hcl52$368
Celecoxib14$365
Cephalexin39$355

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Antioch

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →